Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Châtillon, France, June 29, 2026 DBV Technologies Provides BLA Submission Update for the VIASKIN® Peanut Patch in Children Aged 4 through 7 Years; Working Collaboratively with FDA to Optimize Review ...

DBV to pursue an Accelerated Approval pathway for toddlers ages 1 - 3 years-old BLA submission under Accelerated Approval is subject to completion of a six-month supplemental safety study in toddlers ...

DBV Technologies is presenting new positive Phase 3 data for its VIASKIN Peanut Patch, including results in children with additional atopic conditions. The company has also started a Phase 2 trial in ...

Discusses Regulatory Update and FDA Interactions for Viaskin Peanut Patch in Young Children June 29, 2026 5:00 PM ...

DBV COO Charles Ruban and CDO Laurent Martin. (DBV Technologies) () Two of the leaders responsible for regulatory and product development at DBV Technologies are set to leave the company this month.

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT—CUSIP: 23306J101), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other ...

DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company, today announced that the company shared additional positive data from the ...

DBV Technologies's, (DBV) novel Viaskin patch technology could revolutionise treatment of life-threatening food allergies. Viaskin is based on the principles of allergy immunotherapy, but without ...

Shares of DBV TechnologiesDBVT launched to a three-year high Wednesday after the company reported promising results for its peanut allergy treatment in children ages 4 to 7. The biotech company is ...

DBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at the EAACI Congress 2026 In the Phase 3 VITESSE study, VIASKIN® Peanut Patch demonstrated ...